ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024 SAN DIEGO, April 03, 2024 (GLOBE...
Gesund.ai recognized for achievements in bringing healthcare AI from the lab to the clinic at scale and at speed NEW...
TORONTO, ON / ACCESSWIRE / April 2, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated...
OKLAHOMA CITY, April 2, 2024 /PRNewswire/ -- In a momentous occasion, Oklahoma Proton Center, a leading provider of cutting-edge proton...
Integrating this new solution reflects on Bux Pain Management's commitment to delivering the most advanced and effective care to its...
WESTPORT, CT / ACCESSWIRE / April 2, 2024 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct", or the "Company"), a precision...
Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S.Dr. Radaelli was instrumental in...
Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million...
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programsROCKVILLE, Md., April...
MELBOURNE, Australia, April 02, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...
LUND, SWEDEN / ACCESSWIRE / April 2, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported publication of...
With the addition of MIM Software, GE HealthCare aims to provide clinicians and healthcare systems with increasingly integrated and automated...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in...
Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially...
HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year...
Sales Grew at an Average Rate of 14% Per Quarter During the YearNEW YORK, NY / ACCESSWIRE / April 1,...
Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United KingdomOriginally published on Bristol Myers...
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical...